following the instructions on the web-based form provided. Your comment—including your name and your state—will be placed on the public record of this proceeding, including the https://www.regulations.gov website. As a matter of discretion, the Commission tries to remove individuals’ home contact information from comments before placing them on the regulations.gov site.

If you file your comment on paper, write “Energy Labeling Rule Comment, FTC File No. “ on your comment and on the envelope, and mail it to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, Suite CC–5610 (Annex J), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW, 5th Floor, Suite 5610 (Annex J), Washington, DC 20024. If possible, submit your paper comment to the Commission by courier or overnight service.

Because your comment will be placed on the publicly accessible website at www.regulations.gov, you are solely responsible for making sure that your comment does not include any sensitive or confidential information. In particular, your comment should not include any sensitive personal information, such as your or anyone else’s Social Security number; date of birth; driver’s license number or other state identification number, or foreign country equivalent; passport number; financial account number; or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, such as medical records or other individually identifiable health information. In addition, your comment should not include any “trade secret or any commercial or financial information which . . . is privileged or confidential”—as provided by Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)—including in particular competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names.

Comments containing material for which confidential treatment is requested must be filed in papier form, must be clearly labeled “Confidential,” and must comply with FTC Rule 4.9(c). In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule 4.9(c). Your comment will be kept confidential only if the General Counsel grants your request in accordance with the law and the public interest. Once your comment has been posted publicly at www.regulations.gov, we cannot redact or remove your comment unless you submit a confidentiality request that meets the requirements for such treatment under FTC Rule 4.9(c), and the General Counsel grants that request. The FTC Act and other laws that the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives on or before August 23, 2019. For information on the Commission’s privacy policy, including routine uses permitted by the Privacy Act, see https://www.ftc.gov/site-information/privacy-policy. Heather Hippsley, Deputy General Counsel. [FR Doc. 2019–13383 Filed 6–21–19; 8:45 am] BILING CODE 4160–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention

Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 82 FR 42555, dated September 6, 2017) is amended to reflect the Order of Succession for the Centers for Disease Control and Prevention.

Section C–C, Order of Succession, is hereby amended as follows:

Delete in its entirety Section C–C, Order of Succession, and insert the following:

During the absence or disability of the Director, Centers for Disease Control and Prevention (CDC), or in the event of a vacancy in that office, the first official listed below who is available shall act as Director, except that during a planned period of absence, the Director may specify a different order of succession:

1. Principal Deputy Director
2. Chief Medical Officer
3. Deputy Director for Public Health Service and Implementation Science
4. Deputy Director for Infectious Diseases
5. Director, Center for Preparedness and Response
6. Director, National Institute for Occupational Safety and Health

herri Berger, Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2019–13368 Filed 6–21–19; 8:45 am] BILING CODE 4160–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention

[DOcket Number CDC–2019–0016, NIOSH–325]

Mining Automation and Safety Research Prioritization; Reopening of Comment Period

AGENCY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice and reopening of comment period.

SUMMARY: On March 18, 2019 the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) published a notice in the Federal Register announcing that NIOSH had recently established a research program to address the rapidly expanding area of automation and associated technologies in mining, and that NIOSH was seeking information to inform the prioritization of research to be undertaken by The Institute’s Mining Program. NIOSH is seeking input on priority gaps in knowledge regarding the safety and health implications of humans working with automated equipment and associated technologies in mining, with an emphasis on worker safety and health research in which NIOSH has the comparative advantage, and is unlikely to be undertaken by other federal agencies, academia, or the private sector. Written comments were to be received by May 17, 2019. In response to a request from an interested party, NIOSH is announcing the reopening of the comment period.
DISTRIBUTOR OF AUTOMATION TECHNOLOGIES, THEIR IMPLEMENTATION IN THE UNITED STATES, AND THE HEALTH AND SAFETY CONCERNS ASSOCIATED WITH THE TECHNOLOGY. NIOSH SEeks PUBLIC INPUT ON THE FOLLOWING QUESTIONS:

1. TO WHAT EXTENT WILL AUTOMATION AND ASSOCIATED TECHNOLOGIES BE IMPLEMENTED IN MINING AND IN WHAT TIMEFRAME?

2. WHAT ARE THE RELATED HEALTH AND SAFETY CONCERNS WITH AUTOMATION AND ASSOCIATED TECHNOLOGIES IN MINING?

3. WHAT GAPs EXIST IN OCCUPATIONAL HEALTH AND SAFETY RESEARCH RELATED TO AUTOMATION AND ASSOCIATED TECHNOLOGIES?

While the above questions have priority, NIOSH also seeks public comment on the state of the technology and the health and safety concerns associated with the following specific topics related to automation:

4. WHAT ARE THE MAJOR SAFETY CONCERNS ASSOCIATED WITH HUMANS WORKING NEAR OR INTERACTING WITH AUTOMATED MINING EQUIPMENT? HAVE OTHER ORGANIZATIONS ADDRESSED THE SAFETY CONCERNS ASSOCIATED WITH HUMANS WORKING NEAR OR INTERACTING WITH AUTOMATED MINING EQUIPMENT? IF YES, PLEASE PROVIDE A DESCRIPTION.

5. WHAT RESEARCH HAS BEEN CONDUCTED, OR APPROACHES TAKEN, TO ADDRESS THE POTENTIAL FOR HUMAN COGNITIVE PROCESSING CONFLUATION, MISUNDERSTANDING, AND TASK OR INFORMATION OVERLOAD ASSOCIATED WITH MONITORING OR CONTROLLING AUTOMATED MINING EQUIPMENT OR OTHER MONITORING SYSTEMS (E.G., FLEET MANAGEMENT, ENVIRONMENTAL MONITORING, SAFETY SYSTEMS, HEALTH CARE SYSTEMS)?

6. WHAT IS THE STATE OF THE ART FOR DISPLAY METHODOLOGIES AND TECHNOLOGIES TO PROVIDE MINE PERSONNEL AND EQUIPMENT OPERATORS WITH INFORMATION ON OPERATIONAL STATUS, LOCATION, AND SENSORY AND ENVIRONMENTAL FEEDBACK FROM AUTOMATED MINING EQUIPMENT OR SYSTEMS?

7. WHAT SENSOR TECHNOLOGY IMPROVEMENTS ARE NEEDED TO ENSURE THE SAFETY OF HUMANS WORKING ON OR NEAR AUTOMATED EQUIPMENT?

8. HOW ARE EXISTING METHODS OF BIG DATA ANALYSES APPLIED TO AUTOMATED MINING EQUIPMENT OR SYSTEMS? ARE THERE HEALTH AND SAFETY BENEFITS TO THESE APPLICATIONS? IF YES, PLEASE DESCRIBE.

9. ARE THERE ANY NEEDED IMPROVEMENTS TO GUIDELINES OR INDUSTRY STANDARDS FOR AUTOMATED MINING SYSTEM SAFE DESIGN AND OPERATION PRACTICES? IF YES, PLEASE DESCRIBE.

10. ARE THERE ANY NEEDED IMPROVEMENTS TO TRAINING MATERIALS, TRAINING PROTOCOLS, AND OPERATING PROCEDURES FOR SYSTEM SAFETY DESIGN PRINCIPLES RELATED TO AUTOMATED MINING SYSTEMS? IF YES, PLEASE DESCRIBE.

NIOSH is seeking feedback on the research areas identified above and on any additional knowledge gaps, ideas, innovations, or practice improvements not addressed by these research areas, as well as feedback on how the research areas should be prioritized. NIOSH is especially interested in any creative and new ideas as they relate to protecting the health and safety of miners today and in the future. When possible, NIOSH asks that commenters provide data and citations of relevant research to justify their comments. NIOSH is also seeking key scientific articles addressing worker safety and health related to mining automation that could inform our research activities.

REFERENCES


John J. Howard, Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. 2019–13351 Filed 6–21–19; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2018–N–4609]

Issuance of Priority Review Voucher; Rare Pediatric Disease Product

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Food and Drug Administration Safety and Innovation Act (FDASIA), authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that ZOLGENSMA (onasemnogene abeparvovec-xioi),